Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth
factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, eg …

The epidermal growth factor receptor (EGFR) is a kind of receptor tyrosine kinase (RTK) that
plays a critical role in the initiation and development of malignant tumors via modulating …

With the development of precision medicine, molecular targeted therapy has been widely
used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal …

Gefitinib and erlotinib, which are epidermal growth factor receptor‐(EGFR‐) specific tyrosine
kinase inhibitors (TKIs), are widely used as molecularly targeted drugs for non‐small‐cell …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have led to a
substantial improvement in the prognosis of lung cancer patients by explicitly targeting the …

The epidermal growth factor receptor (EGFR) is a well‐characterized oncogene that is
frequently activated by somatic kinase domain mutations in non‐small cell lung cancer …

Despite the improvement in clinical outcomes derived by the introduction of epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of …

Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …

Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring
epidermal growth factor receptor (EGFR) mutations, especially for those with lung cancer …

Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …